Our aim has always been to push the boundaries of what technology is able to produce, and we are proud to hold a proprietary technology, named ESiNAR-X®, that gives us a unique advantage compared to the rest of the industry. The platform covers unconventional structural design of oligonucleotide-based inhibitors to significantly improve their characteristics in many ways.
The inhibitors based on the ESiNAR-X® platform show:
do not interfere with homologous RNA off-targets
Spontaneous cellular uptake
less frequent and smaller doses can be applied
preclinical studies showed excellent tolerability
trigger biologic effects only in target RNA-containing cells
Remarkable therapeutic efficacy
reduce target RNA levels down to even 0%
fully adaptable to different target RNAs
The progressiveness of the ESiNAR-X® platform is underlined by its theoretical applicability to any diagnosis with a known genetic causality and/or unmet need. The already shown unmatched accuracy in target recognition resulting in the fascinating possibility of eliminating off-target related side effects may facilitate the implementation of this platform not only in clinical practice, but also for research and technology purposes.
Revolutionary improvement in cellular uptake
- Mesenchymal stem cells